Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Total Liabilities (2016 - 2025)

Moleculin Biotech's Total Liabilities history spans 10 years, with the latest figure at $7.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $7.1 million for Q4 2025, up 24.54% from a year ago — trailing twelve months through Dec 2025 was $7.1 million (up 24.54% YoY), and the annual figure for FY2025 was $7.1 million, up 24.54%.
  • Total Liabilities for Q4 2025 was $7.1 million at Moleculin Biotech, down from $47.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $47.3 million in Q3 2025 to a low of $4.4 million in Q3 2023.
  • The 5-year median for Total Liabilities is $7.2 million (2025), against an average of $10.6 million.
  • The sharpest move saw Total Liabilities crashed 54.78% in 2021, then soared 262.94% in 2024.
  • Year by year, Total Liabilities stood at $5.1 million in 2021, then increased by 2.63% to $5.2 million in 2022, then soared by 132.15% to $12.1 million in 2023, then tumbled by 52.92% to $5.7 million in 2024, then increased by 24.54% to $7.1 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $7.1 million, $47.3 million, and $25.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.